Key considerations in the pharmacological management of treatment-resistant depression. (22nd November 2021)

• Record Type: Journal Article
• Authors: Yavi, Mani; Henter, Ioline D.; Park, Lawrence T; Zarate, Carlos
• Is Part Of: Expert opinion on pharmacotherapy. Volume 22:Number 17(2021)
• Page Start: 2405
• Page End: 2415
• Publication Date: 2021-11-22
• Subjects: Augmentation -- biomarkers -- depression -- guidelines -- ketamine -- management -- treatment-resistant; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2021.1951225
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Treatment-resistant depression (TRD) is a complex, multifactorial, and biologically heterogeneous disorder with debilitating outcomes. Understanding individual reasons why patients do not respond to treatment is necessary for improving clinical recommendations regarding medication regimens, augmentation strategies, and alternative treatments. Areas covered: This manuscript reviews evidence-based treatment strategies for the clinical management of TRD. Current developments in the field and potential future recommendations for personalized treatment of TRD are also discussed. Expert opinion: Treatment guidelines for TRD are limited by the heterogeneous nature of the disorder. Furthermore, current strategies reflect this heterogeneity by emphasizing disease characteristics as well as drug trial response or failure. Developing robust biomarkers that could one day be integrated into clinical practice has the potential to advance specific treatment targets and ultimately improve treatment and remission outcomes.